Prof Karim Fizazi (Institut Gustave Roussy, Paris, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the latest updates in prostate cancer from the 2020 ASCO GU meeting in San Francisco.
Prof Merseburger describes the latest data from the TITAN trial, in which the time to second progression (PFS2) result was positive, with the occurrence of no new safety signals. He also explains the concept of this modern endpoint.
The panel discuss the emerging era of personalised medicine and genetic testing in prostate cancer - including the use of PARP inhibitors. Dr Castro provides an overview of the PROfound trial, which showed a benefit of olaparib in patients with DDR-defective metastatic castration-resistant prostate cancer (mCRPC). She also notes that other gene alterations must be investigated in the future, as they could predict treatment response to other therapies in this disease type.
Finally, Prof Fizazi explains the latest data from the CARD trial, which analysed the pain response and health-related quality of life in patients with mCRPC who received cabazitaxel versus abiraterone or enzalutamide.
The panel conclude by discussing the use of cabazitaxel as a standard of care after treatment with docetaxel.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
|Updated results from the TITAN trial|
|Where are we now with PARP inhibitors for the treatment of prostate cancer?|
|Detecting gene alterations in tumour samples|
|Latest developments from the CARD trial|
|Using cabazitaxel as a standard of care after using AR-targeted therapy or docetaxel|